期刊文献+

人附睾蛋白4和糖链抗原125对卵巢癌的诊断价值 被引量:3

Diagnostic Value of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 in Ovarian Cancer
下载PDF
导出
摘要 目的评价人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原125(carbohydrate antigen 125,CA125)对卵巢癌的诊断价值。方法前瞻性收集175名(卵巢癌104名,妇科良性疾病患者71名)在过去3年里因盆腔肿块而来医院就诊的妇科患者,采用酶联免疫吸附剂测定(enzyme-linked immunosorbent assay,ELISA)法检测其血清HE4水平,采用受试者工作特征(receiver operating characteristic curve,ROC)曲线法评价HE4和CA125对卵巢癌的诊断价值,采用logistic回归分析HE4与卵巢癌的关系。结果不论是在绝经还是在未绝经女性中,HE4诊断卵巢癌的ROC曲线下面积(area under the curve,AUC)均高于CA125。在校正CA125之后,HE4>168.5 pmol/L仍然与卵巢癌独立相关(OR=24.54,P<0.01)。结论 HE4对卵巢癌的诊断价值高于CA125,二者的诊断价值并不完全重叠,联合使用有助于提高卵巢癌诊断的准确性。 Objective To evaluate the diagnostic accuracy of serum human epididymis protein 4(HE4) and carbohydrate antigen(CA125) in ovarian cancer. Methods One hundred and seventy five patients with pelvic mass(104 with ovarian cancer and 71 with gynecological benign disease) in our hospital were prospectively enrolled in this study.The serum HE4 concentration was determined by enzyme-linked immunosorbent assay(ELISA).The diagnostic performance of HE4 and CA125 was estimated by receiver operating characteristic(ROC) curve analysis.The association between HE4 and ovarian cancer was evaluated by multivariable logistic regression model. Results The area under curve(AUC) of HE4 was higher than that of CA125,both for pre-and post-menopausal patients.After CA125 correction,serum HE4168.5 pmol/L was associated with ovarian cancer with the odds ration of 24.54(P0.01). Conclusion HE4 has superior diagnostic value to CA125 and the combined utilization of CA125 and HE4 can improve the diagnostic accuracy.
出处 《华南国防医学杂志》 CAS 2012年第2期113-116,共4页 Military Medical Journal of South China
关键词 人附睾蛋白4 糖链抗原125 卵巢癌 诊断 Human Epididymis protein 4 Carbohydrate antigen Ovarian cancer Diagnosis
  • 相关文献

参考文献15

  • 1Aletti GD, Gostout BS, Podratz KC,etal. Ovarian cancer surgical resectability: relative impact of disease, patient status, and sur- geon[J]. Gynecol Oneol, 2006, 100(1): 33-37.
  • 2Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative eval uation of serum CA 125 levels in premenopausal and postmenopa- usal patients with pelvic masses: discrimination of benign from malignant disease[J]. Am J Obstet Gyneeol, 1988, 159 (2) : 341- 346.
  • 3Markman M. The role of CA-125 in the management of ovarian cancer[J]. Oneologist, 1997,2(1) :6 9.
  • 4Bast RC Jr, Badgwell D, Lu Z, et al, New tumor markers: CA125 and beyond[J]. Int J Gynecol Cancer ,2005,15(Suppl 3) : 274-281.
  • 5ttellstrom I, Hellstrom KE. Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma[J]. Expert Opin Med Diagn, 2011,5 (3) : 227-240.
  • 6陈观娣,李志刚,钱德英,毕燕玲,欧阳云雁.人附睾分泌蛋白在盆腔肿物中的诊断价值[J].实用医学杂志,2010,26(15):2774-2776. 被引量:14
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol, 201)8,108 (2) : 402-408.
  • 8Van Gorp T, Cadron I, Despierre E, etal. HE4 and CAl25 as a diagnostic test in ovarian cancer., prospective validation of the Risk of Ovarian Malignancy Algorithm[J].Br J Cancer, 2011, 104(5):863-870.
  • 9Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J]. Gynecol Oncol , 2(311,121 (3) : 487-491.
  • 10Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CAl25 for detecting ovarian cancer: a prospective case-control study in a Korean population[J]. Clin Chem Lab Med,2011,49(3) :527-534.

二级参考文献35

  • 1Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother,2004,58 : 24 -38.
  • 2Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer,2000,82 : 1535-1538.
  • 3Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63 : 3695 -3700.
  • 4Israeli O, Goldring-Aviram A, Rienstein S, et al. In sihco chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet,2005 ,160 :35- 42.
  • 5Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 ( HE4 ) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169.
  • 6Kirchhoff C, Habben I, Ivell R, et al. A major human epididymisspecific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 1991,45: 350- 357.
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108:402-408.
  • 8Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HFA (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63:3695-3700.
  • 9Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet, 1999, 353: 1207-1210.
  • 10Kerbrat P, Lhomme C, Fervers B, et al. Ovarian cancer. Br J Cancer,2001, 84 ( Suppl 2 ) : 18-23.

共引文献144

同被引文献47

  • 1中华人民共和国卫生部.新编常见恶性肿瘤诊治规范(第七分册)[M].北京:中国协和医科大学出版社,1999.668-673.
  • 2Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and im- plications for its use in clinical Screening[J].Gynecol On- col, 2003, 88 (12): 152.
  • 3Lamerz R, Thomas L. Clinical laboratory diagnosis [M ] . 1 st English Edition, Frankfurt, 1998 : 952 - 955.
  • 4Hasholzner U, Baumgartner L, Stieber Pet al. Clinical signifi- cance of the tumor markers CA 125 II and CA 72 - 4 in ovarian carcinoma [J]. Int J Cancer, 1996, 69 (4): 329.
  • 5Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass [J]. Gynecol Oncol, 2008, 108 (2) : 402.
  • 6Kim YM, Whang D, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case control study in a Korean population[J]. Clin Chem Lab Med, 2011. 49 (3) . 527.
  • 7Van Corp T, Cadron I, Despierre E et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm[J].Br J Cancer, 2011, 104 (5): 863.
  • 8Siegel R,Naishadham D,Jemal A. Cancer Statistics, 2013 [J]. CA Cancer J Clin, 2013,63(1):11-30.
  • 9Leung F,Diamandis EP,Kulasingam V. From bench to bedside:discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade[J]. Biomark Med,2012,6(5):613-625.
  • 10Bast RC Jr,Badgwell D,Lu Z,et al. New tumor markers:CA125 and beyond[J]. Int J Gynecol Cancer, 2005,15 (Suppl 3):274-281.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部